Until the widespread introduction of British Comparative Thromboplastin in 19701 paved the way to standardisation, serious difficulties due to variable sensitivities of thromboplastins had impeded the safe and effective control of oral anticoagulant treatment.
Further improvements followed the introduction of the National External Quality Assessment Scheme (NEQAS) in coagulation. 2 The recent availability of primary and secondary World Health Organisation (WHO) reference thromboplastins from human and animal brain3 permitted international conformity in reporting results by an International Normalised Ratio (INR) closely corresponding to the British Corrected Ratio (BCR) (later British Ratio (BR)) and an International Sensitivity Index (ISI) for calibration of thromboplastins. [4] [5] [6] This work has enabled more realistic yet safe recommendations to be made for therapeutic ranges in anticoagulant treatment. 7 8 Concern has arisen, however, about the use of reagents derived from human brain, with recent reports of deaths from Creutzfeldt-Jakob disease (CJD) after the administration of pituitary extracted human growth hormone. 9 The causative agent of CJD is highly resistant to chemical and physical decontamination, including preservation of brain in phenol and formalin.'°F urther anxiety has followed the suggestion that unconventional slow virus infections may be implicated in acquired immune deficiency syndrome (AIDS) encephalopathy," which bears a striking similarity to other spongiform encephalopathies such as CJD, Kuru, and Scrapie. 2 Plasma samples for prothrombin time estimation were tested in duplicate and prepared from venous blood that had been collected into a one tenth volume of 3 8% sodium citrate. The thromboplastin used was the MCR2 and results were expressed as INR (BCR). Normal control plasmas were prepared from a pool of seven healthy volunteer adults and used for day to day precision of the chromogenic peptide substrate assay independent of the lyophilised reference plasma used for construction of standard lines. Thrombotest was done immediately on venous whole blood according to the manufacturer's instructions (Nyegaard and Co, Oslo, Norway). For the chromogenic peptide substrate assay, three independently calibrated lyophilised human plasma samples (prothrombin standard, "Precichrom" I (normal) and "Precichrom" II (artificially depleted of vitamin K dependent clotting factors)) were obtained from Boehringer UK, and test kits for the chromogenic peptide substrate assay were also obtained from these manufacturers.
The chromogenic substrate used was chromozym TH (TOS-GLY-PRO-ARG-pNA) with activation of prothrombin in the presence of calcium, factors V, Xa, and cephalin (rabbit). An automated assay was used based on the method of Svendsen et a126 and modified as fully described previously by the present group.23 Plasma (5 pl) was immediately diluted with 0 I ml of 0 15M sodium chloride, then I ml -of the activator reagent, reconstituted in the proportion 10 ml buffer: 1 ml cephalin: 0 1 ml factors V and Xa was added to the reaction mixture, and after five minutes of incubation at 25°C 0-1 ml chromozym TH was added. The second part of the study, on a small group of patients in initial phase treatment studied over 10 days, showed that a median period of four days (range 3-6-5-5) elapsed before the therapeutic range for chromogenic peptide substrate assay was reached. During this period control was monitored on the basis of INR (BCR).
Discussion
Application of chromogenic substrate analysis to many aspects of haemostasis and thrombosis continues to grow but so far not in the large routine area of oral anticoagulant control. Although patients stabilised on long term oral anticoagulant treatment show a similar reduction in each of the vitamin K dependent factors, there has been reluctance to accept that well established global methods which measure the prothrombin complex (factors X, VII, and II) might safely be replaced by an amidolytic chromogenic assay of only one member of the complex. The present study has shown a good correlation between automated chromogenic peptide substrate assay and the two most widely used global clotting tests, prothrombin time and Thrombotest. In addition, a very good correlation has been found between a one stage clotting assay of prothrombin and the chromogenic method (r = 0-90). 21 Apart from the enormous advantage of chromogenic substrate analysis not depending on reagents derived from human brain, there are other major benefits over biological tests such as prothrombin time, in essence a version of Quick's 50 year old test. 27 Conventional clotting tests permit limited access to automation, to which amidolytic assays are highly susceptible; photometric assays permit more satisfactory standardisation,28 and large batches of samples may quickly be assayed with the standard equipment of clinical chemistry,29 or with smaller numbers by the manual chromogenic method.2' The present study shows that the automated method was easy to apply, accurate, and sensitive, with negligible sample carry over. Very small volumes of plasma were used, Use of chromogenic prothrombin assay to control oral anticoagulant treatment 503 allowing dilution and thereby minimising the influence of inhibitors20 and exposure to laboratory reagents. The method may readily be adapted to allow finger prick sampling.
It has been recommended that selected patients, such as those with cardiac prosthetic valves, would benefit from intensified oral anticoagulation yet could be safely controlled at an INR (BCR) of 3.04.57 8 No special effort was made to intensify control in this study using chromogenic peptide substrate assay results, but this would not have posed problems as the therapeutic range is wide and the lower limit of detection of the assay was 2 5% prothrombin.
A limitation of chromogenic assay of one of the vitamin K dependent factors arises with patients in the initial phase of anticoagulation, as shown in this study. This is because of the wide variation in half life of factors (T1/2), from factor VII at four to six hours to factor II (prothrombin) at 48-96 hours. 29 The resultant therapeutic "hiatus" suggests that neither factor X (T l/2 40-60 hours) nor prothrombin are ideal for initial phase treatment, but it has been suggested that a chromogenic assay of factor 1X (TV/2 18-30 hours) might be suitable,3`while the large biological variation of factor VII, despite a short T l/2, makes it less appropriate.30 The use of a broad spectrum photometric prothrombin time test measuring all members of the prothrombin complex should also permit effective control of initial phase Warfarin treatment.
This study makes no claim other than that an automated chromogenic peptide substrate assay provided safe rapid control in a large group of patients on long term treatment with Warfarin. A good correlation was obtained when the chromogenic results were compared with those obtained from conventional broad spectrum clotting tests. Arguments as to whether these new amidolytic assays provide "Bioequivalence" to traditional methods seem to derive from a reluctance to give up the end point of a fibrin clot rather than on reality.
The withdrawal of MCR because of potential biohazard as a reagent derived from human brain is unfortunate because of its widespread use and tested performance. It is now suggested that automated chromogenic substrate analysis can provide an alternative method, which, potentially, is as susceptible to international standardisation as MCR and dependent to the minimum possible extent on biological reagents. Urgent large scale evaluation of these methods is now required.
